MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity

Chimeric antigen receptor (CAR) αβ T cell adoptive immunotherapy has shown great promise for improving cancer treatment. However, there are several hurdles to overcome for the wide clinical application of CAR-αβ T cells therapy, including side effects and a limited T cells source from cancer patient...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Am J Cancer Res
Glavni autori: Zhai, Xiaochen, You, Fengtao, Xiang, Shufen, Jiang, Licui, Chen, Dan, Li, Yafen, Fan, Shuangshuang, Han, Zhichao, Zhang, Tingting, An, Gangli, Zhang, Bozhen, Chen, Yusheng, Meng, Huimin, Yang, Lin
Format: Artigo
Jezik:Inglês
Izdano: e-Century Publishing Corporation 2021
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7840711/
https://ncbi.nlm.nih.gov/pubmed/33520361
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items